Risperidone

Research use only, not for human use.

An antipsychotic agent with serotonin-S2 and dopamine-D2 antagonistic properties.

An antipsychotic agent with serotonin-S2 and dopamine-D2 antagonistic properties; also has actions at several 5-HT receptor subtypes, adrenergic receptors and histamine H1 receptors.Schizophrenia Approved(In Vitro):Risperidone is a serotonin 5-HT2 receptor blocker, P-Glycoprotein inhibitor and potent dopamine D2 receptor antagonist, with Kis of 4.8, 5.9 nM for 5-HT2A and dopamine D2 receptor, respectively. Risperidone dose-dependently inhibited the release of IL-12 in mature DCs, while the production of IL-10 is dose-dependently increased by Risperidone. A high dose of risperidone can induce TNF-α release from mature DCs. (In Vivo):In the first experiment, body weight is found to be slightly but significantly lower in the Risperidone-treated rats as a function of age. Similar to the first experiment, age-dependent differences in body weight are also observed between the three treatment groups in the second locomotor experiment. Rats treated with the 3.0 mg/kg dose of Risperidone weigh less than vehicle-treated rats on postnatal days 35, 38, and 41. The third locomotor experiment involves larger, mixed-sex litters in contrast to the smaller, single-sex litters used in the first two experiments. As noted for the first two experiments, rats treated with Risperidone in the third experiment gain less weight in an age-dependent manner.

——

——

Apexidone | R-64766 | R64766

GPCR/G Protein

5-HT Receptor

5-HT2A|D2|D2L|D3|α2C-adrenergicreceptor

Neurological Disease

Schizophrenia

106266-06-2

410.4845

C23H27FN4O2

>98% (HPLC)

DMSO: < 4.1 mg/mL

O=C1C(CCN2CCC(C3=NOC4=CC(F)=CC=C34)CC2)=C(C)N=C5N1CCCC5

4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-

(-20℃)

With Ice Pack

≥ 2 years